Progen Of Australia Sees Daylight With Liver Cancer Drug Set For Trial
This article was originally published in PharmAsia News
Executive Summary
Australia's Progen Phamaceuticals may have overcome its boardroom battle with an agreement to repurchase shares to neutralize shareholder complaints. Some shareholders revolted when Progen sought to merge with another company and spent heavily to promote a liver cancer drug now expected to begin trials in Taiwan. The proposed merger collapsed and the company was able to turn back a pair of coup attempts. (Click here for more
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.